Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Baeten, Dominique; Sieper, Joachim; Braun, Jürgen; Baraliakos, Xenofon; Dougados, Maxime; Emery, Paul; Deodhar, Atul; Porter, Brian; Martin, Ruvie; Andersson, Mats; Mpofu, Shephard; B. Richards, Hanno

doi:10.1056/nejmoa1505066

Public

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Published in New England Journal of Medicine • Dec 23, 2015

Authors:

Dominique Baeten

Joachim Sieper

Jürgen Braun

Abstract

BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis. METHODS: In two double-blind trials, we rand...

Subject

Secukinumab

Ankylosing spondylitis

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!